GSA Capital Partners LLP Purchases Shares of 425,186 AirSculpt Technologies, Inc. $AIRS

GSA Capital Partners LLP acquired a new position in AirSculpt Technologies, Inc. (NASDAQ:AIRS) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 425,186 shares of the company’s stock, valued at approximately $1,913,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Larson Financial Group LLC lifted its stake in AirSculpt Technologies by 20.4% during the third quarter. Larson Financial Group LLC now owns 15,137 shares of the company’s stock valued at $121,000 after purchasing an additional 2,561 shares during the last quarter. Wexford Capital LP grew its position in AirSculpt Technologies by 2.6% in the third quarter. Wexford Capital LP now owns 102,614 shares of the company’s stock worth $823,000 after buying an additional 2,614 shares during the last quarter. Rhumbline Advisers grew its position in AirSculpt Technologies by 16.1% in the third quarter. Rhumbline Advisers now owns 20,782 shares of the company’s stock worth $167,000 after buying an additional 2,876 shares during the last quarter. Creative Planning increased its holdings in shares of AirSculpt Technologies by 32.2% in the second quarter. Creative Planning now owns 13,225 shares of the company’s stock valued at $64,000 after buying an additional 3,224 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of AirSculpt Technologies by 239.5% in the third quarter. BNP Paribas Financial Markets now owns 5,952 shares of the company’s stock valued at $48,000 after buying an additional 4,199 shares in the last quarter. 91.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on AIRS. Wall Street Zen cut AirSculpt Technologies from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings upgraded AirSculpt Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Finally, Leerink Partners set a $4.50 target price on shares of AirSculpt Technologies in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $4.50.

AirSculpt Technologies Stock Performance

Shares of AIRS opened at $3.43 on Monday. The company’s 50 day moving average price is $4.53 and its 200 day moving average price is $3.57. AirSculpt Technologies, Inc. has a 52 week low of $1.51 and a 52 week high of $12.00. The company has a market capitalization of $247.30 million, a PE ratio of -19.05 and a beta of 2.33. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.79 and a current ratio of 0.79.

AirSculpt Technologies (NASDAQ:AIRS) last released its quarterly earnings data on Monday, August 10th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.01). The company had revenue of $42.90 million during the quarter, compared to analyst estimates of $44.14 million. AirSculpt Technologies had a negative net margin of 7.79% and a negative return on equity of 5.83%.

AirSculpt Technologies Company Profile

AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.

Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.